Instagram Ern-EyeFacebook Ern-EyeTwitter Ern-EyeLinkedIn Ern-EyeYouTube Ern-EyeHow to use the speech recognition tool?
NCT02521311
RECOVER
This trial does use Clemastine fumarat as a remyelinating agent targeting the
muscarinic receptor on oligodendrocytes around the optic nerve.
Type: Interventional
Status of the trial: Active, Recruiting
Orphan Drug Recognition: NA
Inclusion
- Opening Date: 0000-00-00
- Closing Date: 2022-08-31
Criteria
Inclusion: Patients with acute optic neuritis including the rare forms, inclusion within 2 weeks after onset of ION, RION, CRION, etc
Exclusion: Major ophthalmological disease, myopia >7dpt, simultaneous bilateral ON, pregnancy, other study involvement, (please see protocol for full list)
Children: No
Adults: Yes
Funder Type: other
HCP: Principal investigators
HCP: Other investigators
Within ERN-EYE members
Principal investigators
Other investigators
Workgroups
Neuro-Ophthalmology Rare Diseases (WG2)
Retinal Rare Eye Diseases (WG1)
This ERN is supported by:
